CFO  News Hubb
Advertisement
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact
No Result
View All Result
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact
No Result
View All Result
CFO  News Hubb
No Result
View All Result
Home CFO News

DEA Pressed ADHD-Drug Makers About Impact of Telehealth Firms on Surging Demand

by admin
December 31, 2022
in CFO News



The Drug Enforcement Administration told makers of medication for attention-deficit hyperactivity disorder that it was concerned that “aggressive marketing practices” by companies including telehealth providers could be driving excessive prescriptions, according to a letter from the agency.

While the letter doesn’t cite specific companies, it reflects the DEA’s concerns about marketing efforts for ADHD treatment by telehealth companies such as Cerebral Inc. and Done Global Inc., whose prescribing practices the agency has been investigating. The DEA said in December that it wouldn’t allow any increase in 2023 production of pharmaceutical ingredients that go into Adderall and other stimulants used to treat ADHD. The letter, reviewed by The Wall Street Journal, was sent to drugmakers over the summer but hasn’t previously been reported.



Source link

Previous Post

Roth IRA Rules + Contribution Limits [2023 Update]

Next Post

Links 12/31/2022 | naked capitalism

TRENDING

DG, CRM, AI, CHWY and more
Markets News

DG, CRM, AI, CHWY and more

June 5, 2023
CFO News

RBI likely to maintain pause on interest rate as inflation moves southwards: Experts

June 5, 2023
Economics

Decentralization and Bitcoin | AIER

June 5, 2023
Economics

Is There a Covid Wastewater Spike in New York City?

June 4, 2023
Financial Advisor

Evan Gershkovich and Our Brave New World

June 4, 2023

©  CFO News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact

Newsletter Sign Up

No Result
View All Result
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact

© 2022 CFO News Hubb All rights reserved.